Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer

Published:2022-11 Issue:7 Volume:23 Page:620-629
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Guo Matthew Z.^ORCID,Murray Joseph C.,Ghanem Paola,Voong K Ranh,Hales Russell K.,Ettinger David,Lam Vincent K.,Hann Christine L.,Forde Patrick M.,Brahmer Julie R.,Levy Benjamin P.,Feliciano Josephine L.,Marrone Kristen A.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference42 articles.

1. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival;Casal-Mouriño;Transl Lung Cancer Res,2021

2. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N Engl J Med,2017

3. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial;Spigel;J Clin Oncol,2021

4. Immunotherapy in non-small cell lung cancer harbouring driver mutations;Addeo;Cancer Treat Rev,2021

5. Mutated KRAS is an independent negative prognostic factor for survival in NSCLC stage III disease treated with high-dose radiotherapy;Hallqvist;Lung Cancer Int,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survival;2024-03-22

2. Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series;2024-02-22

3. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation;Clinical Lung Cancer;2023-12

4. New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists – INTERACTION group;Critical Reviews in Oncology/Hematology;2023-10

5. Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer;Expert Review of Anticancer Therapy;2023-08-13